Cephradine

CHEMBL1604 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
349.4 g/mol
LogP
0.4
Phase
4

A first-generation cephalosporin available in both oral and parenteral formulations, used for mild to moderate respiratory, skin, and urinary tract infections caused by gram-positive and some gram-negative bacteria. It was notable for being one of the few early cephalosporins available in both formulation types. Its clinical use has largely declined in favor of more modern antibiotics.

الوزن الجزيئي

349,4000 g/mol

LogP

0,40

TPSA

138,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1

InChI

InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1

Molecular Formula

C16H19N3O4S

HBD / HBA

3 / 6

الروابط القابلة للدوران

4

الذرات الثقيلة

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A first-generation cephalosporin available in both oral and parenteral formulations, used for mild to moderate respiratory, skin, and urinary tract infections caused by gram-positive and some gram-negative bacteria. It was notable for being one of the few early cephalosporins available in both formulation types. Its clinical use has largely declined in favor of more modern antibiotics.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cephradine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1604. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 38103. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.